OpenURL Connection Search

Select item for more details and to access through your institution.

24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients.
Published in:
Drugs, 2020, v. 80, n. 2, p. 167, doi. 10.1007/s40265-019-01248-0
By:
- Craven, E. Randy;
- Walters, Thomas;
- Christie, William C.;
- Day, Douglas G.;
- Lewis, Richard A.;
- Goodkin, Margot L.;
- Chen, Michelle;
- Wangsadipura, Veronica;
- Robinson, Michael R.;
- Bejanian, Marina;
- for the Bimatoprost SR Study Group;
- Aung, Tin;
- Beck, Allen D.;
- Branch, James D.;
- Coote, Michael;
- Crane, Charles J.;
- Crichton, Andrew;
- Day, Steven;
- Durcan, F. Jane;
- Evans, Richard M.
Publication type:
Article
Mean Intraocular Pressure and Progression Based on Corneal Thickness in Primary Open-Angle Glaucoma.
Published in:
Journal of Ocular Pharmacology & Therapeutics, 2006, v. 22, n. 1, p. 26, doi. 10.1089/jop.2006.22.26
By:
- Stewart, William C.;
- Day, Douglas G.;
- Jenkins, Jessica N.;
- Passmore, Carla L.;
- Stewart, Jeanette A.
Publication type:
Article
A Persistency and Economic Analysis of Latanoprost, Bimatoprost, or Beta-Blockers in Patients with Open-Angle Glaucoma or Ocular Hypertension.
Published in:
Journal of Ocular Pharmacology & Therapeutics, 2004, v. 20, n. 5, p. 383, doi. 10.1089/jop.2004.20.383
By:
- Day, Douglas G.;
- Schacknow, Paul N.;
- Sharpe, Elizabeth D.;
- Ellyn, John C.;
- Kulze III, John C.;
- Threlkeld, Anisa B.;
- Jones, Evan D.;
- Brown, Reay H.;
- Jenkins, Jessica N.;
- Stewart, William C.
Publication type:
Article
Therapeutic Success of Latanoprost 0.005% Compared to Brimonidine 0.2% in Patients with Open-Angle Glaucoma or Ocular Hypertension.
Published in:
Journal of Ocular Pharmacology & Therapeutics, 2000, v. 16, n. 6, p. 557, doi. 10.1089/jop.2000.16.557
By:
- Stewart, William C.;
- Day, Douglas G.;
- Stewart, Jeanette A.;
- Holmes, Keri T.;
- Leech, Jessica N.;
- Rowan, Carey T.;
- Schwartz, Gail F.
Publication type:
Article
Comparison of the Efficacy and Safety of Latanoprost 0.005% Compared to Brimonidine 0.2% or Dorzolamide 2% When Added to a Topical beta-Adrenergic Blocker in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension.
Published in:
Journal of Ocular Pharmacology & Therapeutics, 2000, v. 16, n. 3, p. 251, doi. 10.1089/jop.2000.16.251
By:
- Lee, William H.;
- Sharpe, Elizabeth D.;
- Day, Douglas G.;
- Kolker, Allan E.;
- Konstas, Anastasios G.P.;
- Stewart, William C.;
- Rieser, John C.;
- Chopra, Hersh;
- Holmes, Keri T.
Publication type:
Article

Found: 5

24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients.

Mean Intraocular Pressure and Progression Based on Corneal Thickness in Primary Open-Angle Glaucoma.

A Persistency and Economic Analysis of Latanoprost, Bimatoprost, or Beta-Blockers in Patients with Open-Angle Glaucoma or Ocular Hypertension.

Therapeutic Success of Latanoprost 0.005% Compared to Brimonidine 0.2% in Patients with Open-Angle Glaucoma or Ocular Hypertension.

Comparison of the Efficacy and Safety of Latanoprost 0.005% Compared to Brimonidine 0.2% or Dorzolamide 2% When Added to a Topical beta-Adrenergic Blocker in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension.